Back
ProShares Ultra Consumer Discretionary Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Buy
72
UCC
ProShares Ultra Consumer Discretionary
Last Price:
42.02
Seasonality Move:
5.47%
Sell
35
ALNY
Alnylam Pharmaceuticals
Last Price:
275.08
Seasonality Move:
4.48%
Buy
72
ProShares Ultra Consumer Discretionary (UCC)
is a Buy
Is ProShares Ultra Consumer Discretionary a Buy, Sell or Hold?
- The current ProShares Ultra Consumer Discretionary [UCC] share price is $42.51. The Score for UCC is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.
- UCC is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
35
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $274.91. The Score for ALNY is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
UCC Stock Price Chart
What is ProShares Ultra Consumer Discretionary's stock price today?
-
The ProShares Ultra Consumer Discretionary share price today is $42.51
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and UCC is experiencing selling pressure, which indicates risk of future bearish movement.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $274.91
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight buying pressure.
UCC Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.68 | Buy |
| Relative Strength Index (14 RSI): | 70.92 | Buy |
| Chaikin Money Flow: | -939 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (36.08 - 40.78) | Buy |
| Bollinger Bands (100): | (33.62 - 38.78) | Buy |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 3.58 | Buy |
| Relative Strength Index (14 RSI): | 58.54 | Buy |
| Chaikin Money Flow: | 227264 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (257.28 - 277.8) | Buy |
| Bollinger Bands (100): | (173.47 - 275.75) | Buy |
UCC Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 41.41 | Buy |
| 20-day SMA: | 38.92 | Buy |
| 50-day SMA: | 36.72 | Buy |
| 200-day SMA: | 35.65 | Buy |
| 8-day EMA: | 41.38 | Buy |
| 20-day EMA: | 39.57 | Buy |
| 50-day EMA: | 37.74 | Buy |
| 200-day EMA: | 35.38 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 273.53 | Buy |
| 20-day SMA: | 264.94 | Buy |
| 50-day SMA: | 262.48 | Buy |
| 200-day SMA: | 194.67 | Buy |
| 8-day EMA: | 272.54 | Buy |
| 20-day EMA: | 269.21 | Buy |
| 50-day EMA: | 257.72 | Buy |
| 200-day EMA: | 211.82 | Buy |
ProShares Ultra Consumer Discretionary Earnings Growth & UCC Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.57 per share, an increase next quarter of $0.47 per share, an increase this year of $1.33 per share, and an increase next year of $0.70 per share.
ProShares Ultra Consumer Discretionary Technical Analysis
| Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | Sep 23 | Sep 24 | Sep 25 | Sep 26 | Sep 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 16 | 17 | 18 | 19 | 20 | 23 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | Sep 23 | Sep 24 | Sep 25 | Sep 26 | Sep 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 16 | 17 | 18 | 19 | 20 | 23 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||